CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6403 result(s)

mecasermin (Increlex)

Last Updated: May 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: mecasermin
Indications: Increlex (mecasermin) is indicated for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD). SPIGFD is defined by: • Height standard deviation score ≤ –3.0 and; • Basal IGF-1 levels below the 2.5th percentile for age and gender and; • GH sufficiency. • Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypopituitarism, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. SPIGFD includes patients with mutations in the GH receptor (GHR) gene/Laron’s syndrome, post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.

  • Brand Name: Increlex
  • Manufacturer: Ipsen Biopharmaceuticals Canada, Inc.
  • Project Number: SR0692-000
  • Project Status: Pending
  • Submission Type: Initial

semaglutide (Ozempic)

Last Updated: June 18, 2019
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: Diabetes mellitus, type 2

  • Brand Name: Ozempic
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0594-000
  • Project Status: Complete
  • Submission Type: Initial

patiromer (Veltassa)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: patiromer
Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

  • Brand Name: Veltassa
  • Manufacturer: Otsuka Canada Pharmaceuticals Inc.
  • Project Number: SR0665-000
  • Project Status: Active
  • Submission Type: Initial

semaglutide (Rybelsus)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

  • Brand Name: Rybelsus
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Active
  • Submission Type: Initial

dupilumab (Dupixent)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Active
  • Submission Type: Initial

risdiplam (Evrysdi)

Last Updated: May 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

  • Brand Name: Evrysdi
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial